The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shilov Yu.E.

Mental Health Research Center

Baymeeva N.V.

Mental Health Research Center

Brusov O.S.

Mental Health Research Center

Oleĭchik I.V.

Mental Health Research Centre

Sizov S.V.

Mental Health Research Center

Tyurin I.A.

N.V. Sklifosovsky Research Institute of Emergency Medicine of Department of Health of Moscow

Cinnabarinic acid as a potential prognostic marker of schizophrenia

Authors:

Shilov Yu.E., Baymeeva N.V., Brusov O.S., Oleĭchik I.V., Sizov S.V., Tyurin I.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(12): 138‑142

DOI: 10.17116/jnevro2022122121138

Views: 954

Downloaded: 23

Download PDF (RU)
Contact the author
Table of contents

CINNABARINIC ACID AS A POTENTIAL PROGNOSTIC MARKER OF SCHIZOPHRENIA
CINNABARINIC ACID AS A POTENTIAL PROGNOSTIC MARKER OF SCHIZOPHRENIA

To cite this article:

Shilov YuE, Baymeeva NV, Brusov OS, Oleĭchik IV, Sizov SV, Tyurin IA. Cinnabarinic acid as a potential prognostic marker of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(12):138‑142. (In Russ.)
https://doi.org/10.17116/jnevro2022122121138

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
 
МСФ на ЯМ
Close metadata
Recommended articles:
Cere­bral hemo­dynamic diso­rders in patients with schi­zophrenia with concomitant meta­bolic syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):80-85
Clinical and psychopathological characteristics of patients with late-onset schi­zophrenia and schi­zophrenia-like psychoses in clusters identified by biological para­meters. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):137-144
Clinical and psychometric characteristics of cognitive and nega­tive diso­rders in schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):64-71
Controversial issues of diagnosis and theoretical concepts of schi­zophrenia in childhood. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):17-24
Psychological concepts — design of clinical models of schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):25-31
Pharmacotherapy of schi­zophrenia: clinical and some age-related aspe­cts. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):41-50
Clinical systematics of chro­nic delu­sional psychoses in schi­zophrenia and schi­zophrenia-spectrum pathology. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):65-74
Prolonged and chro­nic endo­genous manic and manic-delusional states (psychopathology, typo­logy, dyna­mics, clinic). S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):75-81
Mela­tonergic anti­depressant agomelatine: augmentation of anti­psychotic drugs in treatment of post-schizophrenic depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):5-12
Meta­bolic syndrome in clinical psychiatric practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):13-20

OBJECTIVE

To develop a method for determining cinnabarinic acid (CA) and its immediate precursor 3-hydroxyanthranylic acid (3HAA) in blood plasma and to study their concentrations in patients with schizophrenia before and after treatment.

MATERIAL AND METHODS

The study was carried out on a sample of 23 female patients with an attack-like progredient schizophrenia (F20.01). The levels of CA and 3HAA in blood plasma were measured using liquid chromatography with tandem mass spectrometry.

RESULTS

We found an inverse statistically significant correlation of the sum of CA and 3HAA concentrations before treatment with the total PANSS score after treatment (R=–0.50; p<0.05). There was also an inverse correlation of the CA concentration of before treatment with the total PANSS score after treatment (R=–0.41, p=0.052), statistically significant at the trend level (0.05<p<0.1).

CONCLUSION

CA concentrations in human blood were determined for the first time. The obtained correlations with clinical data show the potential prognostic significance of determining the levels of CA and 3HAA in blood plasma and increase the relevance of further studies.

Keywords:

cinnabarinic acid
3-hydroxyanthranilic acid
kynurenine pathway
schizophrenia

Authors:

Shilov Yu.E.

Mental Health Research Center

Baymeeva N.V.

Mental Health Research Center

Brusov O.S.

Mental Health Research Center

Oleĭchik I.V.

Mental Health Research Centre

Sizov S.V.

Mental Health Research Center

Tyurin I.A.

N.V. Sklifosovsky Research Institute of Emergency Medicine of Department of Health of Moscow

Received:

21.04.2022

Accepted:

18.07.2022

List of references:

  1. Muneer A. Kynurenine pathway of tryptophan metabolism in neuropsychiatric disorders: pathophysiologic and therapeutic considerations. Clin Psychopharmacol Neurosci. 2020;18(4):507-526.  https://doi.org/10.9758/cpn.2020.18.4.507
  2. de Carvalho LP, Bochet P, Rossier J. The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochemistry Int. 1996;28(4):445-452.  https://doi.org/10.1016/0197-0186(95)00091-7
  3. Erhardt S, Schwieler L, Imbeault S, Engberg G. The kynurenine pathway in schizophrenia and bipolar disorder. Neuropharmacology. 2017;112(Pt B):297-306.  https://doi.org/10.1016/j.neuropharm.2016.05.020
  4. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13(7):465-477.  https://doi.org/10.1038/nrn3257
  5. Wonodi I, Stine OC, Sathyasaikumar KV, et al. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry. 2011;68(7):665-674.  https://doi.org/10.1001/archgenpsychiatry.2011.71
  6. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012;37(1):4-15.  https://doi.org/10.1038/npp.2011.181
  7. Plitman E, Iwata Y, Caravaggio F, et al. Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull. 2017;43(4):764-777.  https://doi.org/10.1093/schbul/sbw221
  8. Wang AK, Miller BJ. Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Schizophr Bull. 2018;44(1):75-83.  https://doi.org/10.1093/schbul/sbx035
  9. Lowe MM, Mold JE, Kanwar B, et al. Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 production. PLoS One. 2014;9(2):e87877. Published 2014 Feb 3.  https://doi.org/10.1371/journal.pone.0087877
  10. Pasceri R, Siegel D, Ross D, Moody CJ. Aminophenoxazinones as inhibitors of indoleamine 2,3-dioxygenase (IDO). Synthesis of exfoliazone and chandrananimycin A. J Med Chem. 2013;56(8):3310-3317. https://doi.org/10.1021/jm400049z
  11. Fazio F, Lionetto L, Molinaro G, et al. Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors. Mol Pharmacol. 2012;81(5):643-656.  https://doi.org/10.1124/mol.111.074765
  12. Nicoletti F, Orlando R, Di Menna L, et al. Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia. Front Psychiatry. 2019;10:49. Published 2019 Feb 14.  https://doi.org/10.3389/fpsyt.2019.00049
  13. Maksymetz J, Moran SP, Conn PJ. Targeting metabotropic glutamate receptors for novel treatments of schizophrenia. Mol Brain. 2017;10(1):15. Published 2017 Apr 26.  https://doi.org/10.1186/s13041-017-0293-z
  14. Fazio F, Zappulla C, Notartomaso S, et al. Cinnabarinic acid, an endogenous agonist of type-4 metabotropic glutamate receptor, suppresses experimental autoimmune encephalomyelitis in mice. Neuropharmacology. 2014;81:237-243.  https://doi.org/10.1016/j.neuropharm.2014.02.011
  15. Fraguas D, Díaz-Caneja CM, Ayora M, et al. Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis. Schizophr Bull. 2019;45(4):742-751.  https://doi.org/10.1093/schbul/sby125
  16. Orlovska-Waast S, Köhler-Forsberg O, Brix SW, et al. Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis [published correction appears in Mol Psychiatry. 2019 Mar 12]. Mol Psychiatry. 2019;24(6):869-887.  https://doi.org/10.1038/s41380-018-0220-4
  17. Ulivieri M, Wierońska JM, Lionetto L, et al. The Trace Kynurenine, Cinnabarinic Acid, Displays Potent Antipsychotic-Like Activity in Mice and Its Levels Are Reduced in the Prefrontal Cortex of Individuals Affected by Schizophrenia. Schizophr Bull. 2020;46(6):1471-1481. https://doi.org/10.1093/schbul/sbaa074

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.